2Liaw YF.Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B[J].Antivir Chem Chemother,2001,12supple:67-77.
3Hadziyannis SJ,Papatheodoridis GV,Dimou E,et al.Efficacy of long-term lamivudine monotherapy in patients with hepatitis B eantigen-negative chronic hepatitis B[J].Hepatology,2000,32:847-851.
4Humphries JC,Dixon JS.Antivirals for treatment of chronic hepatitis B:current and future options[J].Intervirology,2003,46:413.
5Liaw YF.Results of Lamivudine trials in Asia[J].J Hepatol,2003,39(supple1):S111-115.
6Lai CL,Dienstag J,Schiff E,et al.Prevalence and clinical correlates of YMMD bariants during lamivudine therapy for patients with chronic hep-atitis B[J].Clin Infect Dis.2003.36:687 -696.
7Chang TT, Lai CL, Lia w YF, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years. Antiviral Therapy 2000 ;5: 44.
8Guan R, Lai CL, Lia w YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001 ; 16 ( Suppl 1 ) : A60.
9Leung N W, Lai CL, Guan R, et al. The effect of longer duration of harbouring lamivudine resistant hepatitis B virus (YMDD mutants) on live histology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001 ;34: 348A.
